This document discusses the targeted activation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It explores the use of Gapmers as a potential therapeutic intervention for cystic fibrosis (CF) patients by inhibiting the expression of BGas introns, which suppress the CFTR gene. The document presents data on the reduction in BGas expression, increased CFTR gene expression, and protein levels in healthy and F508del-mutated CF cell lines. The findings suggest that targeted activation of CFTR through Gapmers could be a promising molecular treatment approach for CF.